EUCTR2021-000566-14-CZ进行中（未招募）1 期
Post-authorization Phase IV effectiveness and safety multicentric study of COVID-19 vaccines – CoVigi
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 565
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Age = 18 years
- •2) Willingness to participate in the study expressed by signing the informed consent form
- •A subject can be included in a cohort of newly enrolled subjects with an already fully applied vaccination scheme according to SmPC, if they additionally meet the following criteria:
- •1) Patient in the care of the Department of Internal Hematology and Oncology, University Hospital Brno
- •2) Planned booster dose (3rd dose for the originally two-dose schedule, or 2nd dose for the single-dose schedule)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 282
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 283
排除标准
- •1) Pregnancy, breastfeeding
- •2) Inadequacy of patient classification based on the individual assessment of the study physician
研究者
相似试验
招募中
1 期
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Prostate cancerCTIS2023-503208-94-00ovartis Pharma AG704
Unknown
4 期
Post marketing study to evaluate the side effects and bleeding controlling effectiveness of RECOMBINATE (Factor VIII) drug.CTRI/2011/11/002135Baxter India Pvt Ltd50
进行中（未招募）
不适用
Post-authorization safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - NDEUCTR2007-005728-34-ITHEXAL BIOTECH1,500
招募中
Unknown
A Post approval observational study to assess safety and effectiveness of oral digestive ENZYME tablets in stomach upset.CTRI/2023/08/056549ot applicable
进行中（未招募）
4 期
Clinical study to learn more about how Kyprolis works to fight against or help to control the disease and if causes side effects in Indian subjects with relapsed or refractory multiple myeloma.CTRI/2019/06/019535Amgen Technology Pvt Ltd